BLRX

BioLineRx Share Price - BLRX

1.80
0.04 (2.27%)
Upgrade to Real-Time
Afterhours (Closed)
1.80
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
BioLineRx Ltd BLRX NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
0.04 2.27% 1.80 20:00:00
Close Price Low Price High Price Open Price Previous Close
1.75 1.71 1.79 1.75 1.76
Bid Price Ask Price Spread News
1.71 1.82 0.11 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume
239 90,943  1.73  157,425 268,726
Last Trade Time Type Quantity Stock Price Currency
19:45:06 formt 100  1.80 USD

BioLineRx Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 35.58M 19.77M 19.77M  -  - -2.70 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  - 0.00% - -

more financials information »

News BioLineRx

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

BLRX Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year0.000.000.000.0000.000.0%
3 Years0.000.000.000.0000.000.0%
5 Years0.000.000.000.0000.000.0%

BioLine Rx Ltd is a clinical-stage biopharmaceutical development company with a strategic focus on oncology. Its development and commercialization pipeline consist of two clinical-stage therapeutic candidates - Motixafortide (BL-8040), a novel peptide for the treatment of solid tumors, hematological malignancies and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, it has an off- strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions.


Your Recent History
NASDAQ
BLRX
BioLineRx
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.